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The Management of Performance Anxiety
with Beta-Adrenergic Blocking Agents
Jam es A. Bourgeoi s, M.D.

Abs tract

Performance anxiety consists qf several symptoms experienced in the context qf public
performance and is classified in DS M-III-R under social phobia. Performance anxiety must be
distinguished from panic disorder, generalized social phobia, and generalized anxiety disorder.
Petformance anxiety symptoms can be detrimental to both petformer and performance. These
symptoms can be controlled by the j udicious use of beta-adrenergic blocking agents. The use qf
beta-adrenergic blocking agents should be considered as part of a psychiatric stress-management
programJor these patients.
The ph en omenon of pe rfo r m ance a nxiety (or "s tage fri ght ") has been a pprec ia ted for man y years . Th e sym pto ms a re not ed imm ed iat ely prior to a nd du ri ng
va rious performance tasks , e.g., music, public speaking, a t hletics, and t est tak ing,
a nd a re referabl e to th e sympath etic nervous sys te m . Althou gh no standard seri es of
sym pto ms spec ific to this cond itio n has been develop ed , tachyca rd ia / pa lpita t io ns,
trem or, a nd swe a t ing a re cite d most common ly, wit h various other sym p to ms list ed
less co ns iste n t ly (1- 16, T abl e I).
A s mall, manageable a mo u nt of a u to no m ic aro usal may we ll be ada p t ive by
se rving to incr ease th e perform er's e ne rgy . For many o t her perform ers , however ,
th ese sympt om s are excessive a nd coun te r prod uct ive. Wit ness t he viol in ist or arch er
with excessive tremor, th e trumpet er with dry mouth a nd short ness of br eath , or th e
ac to r with excessive swea ting. This paper will exa mine th e eva lua t ion and m a nagem ent of performance a nxie ty sym ptoms.

DESCRIPTI O N AND DIFFERENfIAL DIAGNO SIS

Perform an ce anxiety is classifi ed in DSM-III-R as soc ia l ph obia (300 .23) ( 17).
These crite ria includ e: a persist ent fear of situa tions in wh ich th e person is expose d to
sc ru t iny by o t he rs, a nd fears th at he / sh e may act in a hu m ilia t ing or e m ba r rass ing
m ann er; expos u re to th e st im ulus provok es a n anxie ty response; th e phobic sit ua t ion
is avo ide d or e nd u re d with grea t a nxie ty; a nd th e avo ida nt be havior int erferes with
occ upa t iona l functi oning. DSM-III-R di stingui sh es bet ween t hos e person s with
"ge ne ra lized" socia l phobia from thos e with " d isc re te" soc ia l ph ob ia whic h is limit ed
to performance situations by th e cavea t that th e ge ne ralized type desc rib es those
persons for whom th e phobia sit uatio n includes most soc ia l sit ua t ions. A st udy by
13
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H eimberg, H op e, Dod ge, a nd Beck er ( 18) co m pared a group of ge ne ra lized soc ial
ph obics to a group who were ph obi c for public speaking only. They found t he
ge ne ra lized soc ial ph obi cs to be lower-functi oning, a nd to have more severe ph obi c
sym ptoms th an the public speaking phobics. The public speaking phobi cs wer e fou nd
to hav e a noticeabl y gr eater incr ease in heart rat e in resp on se to a performance
challe nge , as well as ove re stim a ting th e visibi lity of t he ir anxiety symptoms a nd
unde res timating th e qu ality of thei r pe rform an ce whil e bein g obs erved.
Turne r a nd Beid el ( 19) st udie d a population of socially anxious person s who
were as ked to give a speech. They found a sign ificant inc rease in blood pr essure
du ring th e pe r for mance task for a subgroup d escribed with " high ph ysiologica l
react ivity. " Their st udy did no t use DSM-III cri teria for social phobia, and th e specific
symptoms of pe rform ance a nxie ty vs. ge ne ra lize d socia l ph obia were not addressed.
An import ant distincti on m ust be m ad e bet wee n social phobia a nd pani c
disorder. Althou gh th e ph ysical a nd cog nitive sym p to ms of t he two cond itions show
co nside ra ble overlap, th e panic disorder pat ient experie nces symp tom attacks as
u nexp ect ed a nd not tri gge red by sit ua tions in whi ch th e perso n is the focus of
a tte n tion by oth ers (17) . When th e pani c di sord er pat ien t develops phobic avoidance
of soci a l sit ua tions, it is a fter th e onse t of panic d isord er and du e to fear of having a
panic a ttack (ofte n in a non social sit ua tio n) , while t he soc ia l phobic is a fra id of ac ting
in an em ba rrassing or humili ating way (20). Th e di st inct ion between socia l ph obia
and pa nic disord e r has both di agn ostic a nd t he ra peutic importance, as treatm ent
wit h tri cyclic a n tide p ressants is recom m ended for pan ic disord er, but is gen erall y
ine ffec tive for soc ia l ph obi a (2 1). T o illus t ra te th is poin t, Pohl , Balon and Yeragani
(22) rep ort ed a case of a mu sician who first develop ed pan ic a ttacks in a vari et y of
sit ua tions . Eve n t ua lly, th e sym ptoms of palpitation s, swea ting, chest tightness,
trembling, feelings of panic and fears of "going crazy" occ urred only with musical
perform ance. H e res po nde d bri efly to prop ran olol, but eve n t ua lly was su ccessfull y
treate d wit h imprimine. Becau se hi s init ial sym ptoms were spon taneous, thi s patien t
is mo re acc ura te ly d escrib ed as havin g panic disord e r ra t her t ha n socia l phobia.
It is pos t ula te d th a t patient s wit h soc ia l ph ob ia lim ited to performance sit ua tions a re u nu su all y res po nsive to th e peripheral somatic cues that result fr om
ad re nergic ac tivation (2 1). There is some evide nce that such patients show a mor e
d ra m at ic ca rdiovascula r resp on se to stressful performance stimu li ( 18). The patient
noti ces th e so ma tic sym pto ms (which nearly uniformly include tachyca rd ia, sweating,
a nd trem or) a nd th en d evelop s a cog nitive percept th at ot hers will be particul arl y
perceptive of th es e somatic sym p toms (18,21). This result s in a vicious cycle wherein
t he somatic sym ptoms lead to th e hypersen sitive cog nitions, lead ing to gr ea ter
pe ripheral sym ptoms in a positive fee dbac k loop . This prop osed mechanism is in
con t rast to th e ce n t rally driven mech anism felt to be responsible for pani c dis order.
Leib owit z, Gorm an , Fyer a nd Klein not ed th at DSM-III social phobia patients had a
subs ta n tia lly lowe r incid en ce of lact a te-indu ced pa nic symptoms th an did patie nt s
suffe ring fro m panic disorder with agorapho bia, furt her supporting a neuroch emi cal
differen ce between th ese two conditions (2 1).
Social phobia mu st a lso be disti ngui sh ed fro m avo idan t personality disorde r,
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whi ch represents a more lon g-st anding patt ern of soc ia l avo idance with less lik elihood of dis cr e t e episode s of ph ysical symp to ms . Pati ents wit h socia l ph obi a a re a lso
pron e to a ffec tive illn ess and subst ance a buse , whi ch m ay be att empts to manage
a nxie ty sympt oms (17). Agras ( 15) not ed a sig nifica n t incid ence of com ple te avoida nce of th e phobic sit ua t ion , occupational cha nge, ami a nt icipa tory lise of alcohol in
pati ent s with public spe a king or mu sical pe rformance form s of soc ia l phobia.
PERFORM ANCE ANXI ETY IN PERFORIvIER GRO UPS

The fr equ en cy of intrusive perform an ce anxi et y eve n a mo ng seaso ned performe rs is sur p rising ly high. Performan ce a nxiety does no t necessa rily decr ease with
e it he r increasin g musical pr oficien cy or perfor mance ex pe rience . Among well-known
perform ers, Arthur Ruben st ein , Pablo Casals, an d Carly Simon a re said to have
su ffere d from sig nifica n t performance a nx ie ty (23). W esn er, Noyes , and Davis ( 10),
in a survey of universit y music stud ents a nd faculty, found th a t 16% of t he respondent s felt th at th eir performance was m ark edl y impaired by t heir anx iety sympt om s,
with poor co nce nt ra tion, rapid hea rtbeat , t re mo r, sweati ng and d ry mouth th e mo st
co m mo nly rep ort ed perform an ce a nxie ty sym pto ms. Aud it ion s a nd solo performances (whe re in th e player is th e mo st exposed to the list e ne r's scrutiny) were ci te d
as being "quite a bit" or "ext re me ly" anxi et y pr ovoking by a majority of th e
resp ondent s. The a u t ho rs a lso ask ed a bo u t other a nx ie ty symptoms including panic
a ttacks a nd report ed th at 27% a nd 34% of th ei r sa mple claim ed to be " ne rvo us
pe rso ns" a nd to have had panic a ttacks, resp ectively. Of so m e not e is th at th eir
qu esti onn aire did not defin e th ese terms fu r t her. Th e st udy showed very littl e use of
a lcohol or drugs of a buse, while 4% of th e " im pa ire d " g ro up ad m itted to t he us e of
pr escription m edications to cont ro l perform an ce a nx ie ty sym ptoms; beta-blocking
age n ts were no t specifica lly qu estion ed fo r. Thou gh specific psychological psych othera pe u tic t echniqu es we re no t det a iled , ove r 50% of t he responde nts re por ted th eir use
for th e managem ent of performan ce a nx iety.
Fishbein a nd Middlest adt (24 ) com ple te d a m aj or survey of over 2,000 professiona l mu sicians and found that 24% of th e resp ond ents report ed "s ta ge fright " as a
sig nifica n t m edi cal pr obl em ; it wa s (a long with eye strain) th ei r most rep ort ed
m edi cal co m pla in t. H owever, th e a u t hors did not define " sta ge frig ht" in term s of
dis cret e ph ysical and psych ologi cal sym pto ms . They also not ed "acu t e anxiet y" as
being report ed as a m edi cal probl em by 13% of th ei r resp ond e nt s. Pe r ha ps som e of
this latt er g ro up had panic di sorder sym ptoms not temporall y-connected to perform an ce. Other psych ologic sym p to ms cite d by t he resp ondents were depression in
17%, slee p di sturban ces in 14%, a nd co nce rn ove r alcoho l co nsu m pt io n in 20%.
Twenty-seven percent of th e respondent s had used bet a- adren ergic block ing age nts
(70 % of th ese were " non-pre scribe d occasional " us ers). O ccasion al use of betablo ck ers was most fr equ ent before auditions, solo recit al s, or difficul t or chestrat al
performances. The vas t majority of those mu sicians wh o used beta-blockers on suc h
a n occasio na l basis report ed success in stage fri ght sym ptom con t rol. Twenty-five
percent of th e stage fr igh t suffere rs had resor te d to psych ological co unseling (tec h-
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niqu e un sp ecified ) for sym p to m re lie f, wit h 60% re po r ti ng s ucc ess. It has been
cla im ed th at conflicts ove r ca ree r cho ice a nd d om esti c tu rm oil may be somewha t
r esp on sible for the ex pe r ie nce of perform ance a n xie ty in th e m usicia n (25) .
V a rious a t hle t ic eve n ts which requ ir e fine m o tor co ntro l can be adversely
a ffected by the ph ysical symptoms of perform ance a nx ie ty . For example , the rifl e
shoo ter o r a rc he r ca n be rend e red un st ead y by palpit at ion s or tremor. The bowler,
billiards pl ayer, or go lfer will be ill-served by ei t her sweaty pal m s or hand tremor. At a
m ore cog nit ive level , focu sing on ot he rs' abili ty to see t he signs of performance
a nx ie ty ca n serve to di st r act the co m pe t ito r a nd ke ep him from concentrating on his
a t hle t ic skill (26).
Actors a nd public speake rs ca n be a ffec te d by perform ance anxiety symptoms as
well. It is diffi cult to m aintain conce n t ra t ion on one 's speaking performan ce in th e
face of palpit a ti on s, sweat ing, tremor or the ot he r sym p to ms of performance anxi et y.
Also troubl esom e t o th e speake r a re dry m outh , vocal t remor, and shortn ess of
breath .

BETA-ADRE NER GIC BLO CKING AGENT S-RATI O NALE FO R T REATMENT

Bet a-adrenergic blo cking age n ts a re thought to ac t per iphe rall y to block th e
somat ic co m po ne n ts of th e anxi et y sta te . These sympto m s incl ud e tachycardia /
palpi t ation s, trem or, a nd swea t ing, as well as vario us ot her symptoms (Table I). By
block ade of the periph eral manifest a ti on s of a nx iety, th e pa ti en t perce ives les s
a nxie ty, thu s blunting th e positive feedback loop where in the pe rception of somatic
a nx ie ty sym p to ms le ad s to a nx io us thou ghts whi ch leads to more somat ic symptoms.
It has lon g been a p p recia te d that sym pat he t ic ne rvou s system di sch a rge is associat ed
wi th suc h sym p to ms ; beta- adren ergic block ad e is thus a t rea t m e nt consist ent with
ph ysiol ogy.
It has ge ne rally been sho wn that the ac tio n of bet a-block e rs in reduci ng anxi et y
sym p to ms is ba sed on th eir periph eral ac t ions; bet a-bl ock in g agents kn ow n not to
pen etrat e the blood-brain barri er may redu ce a nxie ty sym p to ms, a nd a nx iolysis has
been not ed with beta-block er do ses too low to ac h ieve ce n t ral ph ysiologica l effects
(27) . Furth erm ore, in a nxie ty sta tes, th e ac tion of beta-block e rs on periph eral
m anifestation s are more clearly redu ced th an a re th e purely psychic m an ifesta t ions,
a nd va ri ou s performance ac ts a re improved with just th e periph er al actions of
bet a-block ers (11 ,13) .
A st udy by Mills, Dim sd al e, Zi egl er et a l. (28) found lymphocyt e beta-adren ergic
receptor d ensity a nd sensitivity to corre la te with the ca rd iovascu la r response to a
m en tal st resso r. Thi s is of int erest in that excess card iovascu lar reactivity may
predict the lat er d evelopm ent of ca rdi ovascula r di seas e ; it is pl ausible that ex ces s
card iovasc u lar r eactivity may co r re la te wit h the d egre e of performance anxi et y
sym p to ms as well.
Fo st er, Evans a nd H ardca stl e (29) moni tor ed th e pu lse rates of surgeons whil e
they perform ed op erations a nd whil e t hey a tte nde d out patien t clinics . A typical
increa se in pulse to a m ean of 121 BPM was see n in th e surgeo ns while they were
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TABLE 1.

Signs /Symptoms of Performance Anxiety (1-16)
Neuropsychiatric
TREMOR
nervousness
fea r
increased ta lking
rest less ness
decr eased concentration
incr ea sed mu scle ten sion
"deta ched" feeling
tin gling
Cardiovascu lar
TACHYCARDI A/ PALPITATI O NS
hypert ension
Respi rat ory
Shor t ness of Breath
Gas trointest ina l
Nausea
Diar rhea
Der ma tologic
SWEAT ING
flush ed skin/ blus hing
Other
Dr y Mout h
Voice Ch ange
Urg en cy to Mictu rit ion

operating; 40 m g of oxpre no lol red uced th e d uring surgery pu lse of th e surgeo ns to a
m ea n of 84 BPM.
C h ro nic ad m inist ration of be ta-adren ergic blocking ag ents is associat ed with a n
incr eas e in th e number of bet a-adren ergic recept or s; thus a brupt d iscontinu ation of
th ese age n ts ca n ca use a withdrawal synd ro m e. The wit hdrawal symptoms may
includ e a nx ie ty, tremulou sn ess, sweat ing an d t ach yca rd ia (16) . The notable sim ilarity between th ese sym pto ms a nd t he sym ptoms of performance anx iet y m ak e th e
" pe riphe ral so ma t ic cues " mod el of perform an ce a nx iety a nd it s m an agem ent by
bet a-adren ergic blo ckad e all t he more plau sibl e .
STUDIES OF BETA-ADRENERGIC BLO C KAD E FO R PER FO RMANC E ANXI ETY
AN D/O R SOCIAL PH OBIA (TA BLE 2)

H artley, U ngape n, Davi e a nd Spe nce r ( I) st udied public speakers who received
eit he r 40 m g propranolol or placeb o six ty to nin ety minut es prior to giving a speech.
In part of th eir study, " a nxious" group was se lect ed on the bas is of th eir high scores
on a sca le of trait a nxie ty . Followi ng th e sp eech , th e subj ects compl et ed a scal e of state
a nxi e ty. Propranolol was associa te d wit h a sign ificant d ecrease in th e state a nxie ty

00

TABLE 2.

Studies of Beta-Adrenergic Blocking Agent s for Symptom s of Performance Anxiety/Social Phobia
Authors:

Medications :

Design :

Perform ance
T ask:

Hart ley, Unga pe n, Propranolol
Davie, et a l. ( I)
40 mg

Doub le Blind
Cross-over
Placebo Co ntrolled

Pub lic Spea king

j ames, Pear son ,
Griffith, Newbu ry (2)

O xpr en olol
40 mg

Doub le Blind
C ross-ove r
Placebo Co ntr olled

Mu sic (Ins trument al-st rings)

j am es, Savag e (3)

Na dolol
40 mg
Diazep am
2 mg

Doubl e Blind
C ross-over
Placebo Co ntrolled

Mu sic (lns tru me nta l-str ings)

Brant igan, Branti- Propr an olol
gan, joseph (4)
40 mg
T erbuta line
Ne fte l, Adler ,
Kappeli, et al.
(30)

Atenolol
100 mg

Doubl e Blind
Cross-over
Placebo Co ntr olled
Doubl e Blind
Placebo Cont rolled

Mu sic (Ins trumen tal)

Mu sic (ln strumen ta l-str ings)

Result s:

Comment s:

Pr opr an olol delayed recall
Pr opr an olol decreased an xiet y
of item s in some subjects,
sympto ms in nonverbal beh avraising qu esti on of a cenior of anx ious subjects a nd detr al action .
creased pulse rat e in all subj ect s.
Oxpren olol decr eased pul se, sysOxprenolol had no effect on
tolic BP, tr emor, self-ra tings of
mem ory, and had mor e
nervou sn ess, and improved mueffect on first day of
tr eatment.
sic performan ce scores . Ca lming effect a tt ribute d to oxpr enolol.
Na do lol was chose n for it s
Nado lol decreased skin flushin g,
hydroph ilicit y.
se lf-ra t ing of trembling, pul se
rate, and improved bowing
techn iqu e, int on ati on , and
overa ll mu sical performan ce.
T erbut alin e wor sen ed perPropr an olol decr eased pulse
form ance anxiety sym pand improved self-ra tings
sym pto ms, mus ical perfo rtoms.
mance, and saliva volum e.
At enolol decreas ed pulse and self- Atenolol was chose n for its
ra tin gs of perfo rm an ce anxi ety
hydrophilicit y. Placebo
gro up showed incr eased
sympt om s during performance
only; ate nolol improved some
pu lse beginning 90 second s befor e performance
techni cal as pec ts of perforthat last ed throu ghout
man ce.
performa nce.
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TABLE 2.
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Continued
Author s:
Gat es, Saegert,
Wilson , et al.
(5)

Medication s:

Design :

Nadolol
20,40,80
mg

Doubl e Blind
Placebo Co ntr olled

Liden, Go t tfries
(6)

Alpre nolol
50, 100
mg

J am es, Buygoyne,
Savage (3 1)

Pind olol
5 mg

Brewer (32)

Doubl e Blind
Cross-over
Placebo Contr olled
Doubl e Blind
Placebo Con tro lled

Performan ce
Task:
Mu sic (Singi ng)

Music (Instr ume n ta l)

Mu sic (In str umen ta l)

Prop ranolol
10-80 mg

Placebo Co ntrolled

Un ivers ity Exam inations

Taggart , Carruth ers , Som erville ( 13)

Oxpreno lol
40 mg

Public Speaking

Dr ew, Barnes,
Evan s (33)

Propran olol
120 mg

Double Blind
Cross-over
Placebo-Controlled
Doub le Blind
Cross-over
Placebo-Con tr olled

Verbal Reasonin g
Men ta l Arithmeti c

t"'l

a::
t"'l
Results:

Co m me nts:

Na do lol d ecreased intra-p erfor man ce pul se rat e at all doses.
20 mg dose-improved performa nce by se lf-rati ng andj udges' rat ings. 40 mg, 80 mg
doses- worsen ed perform an ce
by self-ra t ing and judges' ratings.
Alpr enolol decr eased pu lse rat e,
tremor, and blocked incr ease in
mu scle ton e.

Man y subjects describ ed
decr eased "e ne rgy " at
high er doses. Sma ll nu mber of subjects prevented
a uthors fro m concluding
clear ben efit of lower
dose.

Pind olol decrea sed anx iety, pul se,
blood press ure increase, a nd
improved subjective eva lua tion
of performance.
Prop ra nolol "suggest ive" of irnproved performance in " high
test anx iety" su bje cts.
Oxpreno lol blocked tachycardia
and EKG abnorma lities, relieved anxi et y sympto ms.
Propran olol associa te d with irnpr oved perform an ce.
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Subjec ts were se lf-selecte d
for performan ce anxi et y
sympto ms.
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Pind olol had no effect on
pea k Aows.
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Propranolol doses wer e adj usted to achieve res ting
pul se rat e of 55-65 BPM.
7 patien ts in oxprenolol
group had known coronary artery disease.
Stude nts rep orting anxiety
symptoms wer e help ed
most. Side effects report ed in nearl y half of
subjects on pro pr an olol.
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TABLE 2.

Continued
Authors:
Siiton en ,Janne
(34)

Medicat ion s:
Oxpreno lol
40 mg

Liebowitz, GorAtenolol
man, Fyer, et a!'
50, 100
( I I, 14)
mg /day
Ph enelzine
15- 90
mg/day
Gorm an , Liebow- At enolol
50,100
itz, Fyer , et a!'
( 12)
mg/d ay

Design :
Doub le Blind
Cross-over
Placebo-Controlled
Doub le Blind
Placebo Con trolled

Op en
No Placebo

Performance
T ask:
Bowling

Non e

None

Results:

Co mme nts :

Oxprenolol blocked ta chycardia ,
Subjects withou t high ca rdiovascu lar reactivity had
improved scor es in subgroup
wor se scores wit h oxprewith high cardiovascular reacno lo!'
tivit y.
" Discre te" social ph obia
Ph en elzin e decr eased sympto ms
simila r to performan ce
of ge ne ralized social phobia;
ate nolol was no bett er than plaanxi ety.
cebo for generalized social phobia, but effect ive for discret e
social ph obia .
50% of pati ent s with social
50% of patients with " mar ked"
phobia in study had hisand 40% of patient s with
" moderate" improvem ent in
tory of depression ; 50%
had hist or y of a lcoho l
socia l ph obia self-ra t ings.
abuse . Perform an ce anxiety pati ent s not distinguished fro m th ose with
ge ne ra lized socia l ph obia .
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scores, as well as a decr ease in th e observe r ratings for sig ns of a nxie ty. Of not e is t he
fact th at th e obs erve r in strum ent was a n " a nxiousne ss" scal e of one to 20; it
apparently did not add re ss individu al ph ysical sym p to ms of a nxi et y. When t he
authors co m pa re d a g ro up of a nx ious subj ects (on th e basis of sta te a nd tra it a nx iety
scales) to a non- anxiou s gro u p, it was found th at pr opran olol sig nifica n t ly reduced
th e pul se rat e in both g ro u ps, whil e ob servers looking for pau ses, sta m me ring,
giggling and tremor not ed less speech-rela te d a nxie ty be havi o r in th e anxio us
su bj ec ts following propran olol , but no effect of th e d ru g on th e non-anxious. This
distinction impli es a neuroch emical differen ce between th e two g ro u ps. Some impa irm ent in recall of so me it em s by a nxious subj ects seen with pr opra nolol sugges ted a
ce n t ra l effect of propranolol.
j am es , Griffith , Pearson a nd Newbu ry (2) st udied st ring m us icians receiving 40
m g oxprenolol vs. placeb o. The subj ects played a solo piece befor e a n a ud ie nc e and
co m ple te d rating sca les for a nx ie ty before a nd afte r t he pe rfor m a nce, as well as
assessments of performance. Blood pressure and pul se were mo nitored , a nd expe rienced music rat ers eva luate d th e perform an ce for va riou s t echnical points, one of
whi ch wa s lack of tremor. When re cei ving ox pr eno lol, th e subjects had lowe r pulse
a nd blood pressure, less nervou sn ess, and improv em ent in m usical performan ce. T he
a rea of g reates t improvem ent wit h th e drug was with t re mor. The subjects we re 110/
se lec t ed for nervou sn ess, a nd t hos e with a hist ory of ne rvou s o r m ent al illness were
excluded . The oxpren olol wa s not ed to hav e a grea t er effec t befor e t he firs t
perform an ce, sugges t ing th at sym p to ms may d ecr ease wit h t im e. A weakn ess of th is
st udy was th at th e a u t ho rs did not inq uire as to specific ph ysical sym ptoms experie nced by th e subj ect s.
james a nd Savag e (3) co m pa re d th e effects of 40 m g nad olol and 2 mg d ia zep a m
on st ring musicians in a placeb o-con troll ed s tudy. Na do lol was chose n fo r its
hydrophilicit y a nd low lik elihood of e NS side effects . Subj ects wit h a h ist ory of
nervous illn ess were exclud ed. The obse rve rs not ed th e subjects' specific ph ysical
sig ns (t re mo r, swe a ting , flush ed ski n, talking a nd restl essness) ; t he subjects rat ed
th emselves for palpitations, loss of conce n t ra t ion , gas t ro in test inal ups et , t re m bling,
d etach ed feeling, and fr equ en cy of micturition, as well as a self-rating on th e qu ality
of th eir performance. The nadolol g ro up was not ed to be pa ler than co n t rols. Four of
14 subjects had tremor with placeb o; all of th ese improved a ft e r nad olol. Nadolol was
as sociat ed with a lower pulse and improvem ent in bowin g t echniqu e a nd in to na t ion.
No differen ce wa s found in m ood st at es on a self-ra t ing sca le wit h ac t ive drug.
Diazepam was associat ed with a minor det erioration in pe rfo rm an ce.
Brantigan, Brantigan and j oseph (4) st ud ied in strumenta l mu sicia ns using
pr opranolol and th e bet a- adren ergic a goni st terbut al ine. The subjects were eva luat ed for overall performance, nervou sn ess, a nd somat ic sym pto ms . T he pro pranolol
group showed a signifi cant decr ea se in heart rat e, a n improve m en t in saliva producti on , a nd improvem ent in th e se lf-re po r ts of va rious ph ysical sym ptoms of perfo rmance anxi ety. The terbutaline, as pr edi ct ed incr ea sed th e symptom s. The subjects'
sta te (but not trait) anxi et y decreased with propranolol. The resu lts of th e m usic
rat ers' eva lua t ion of subjects' pe rformance in part of t heir st udy wa s sig nifica ntly
bett er with propranolol.
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Ne fte l, Ad ler, Kappcli e t a I. (30) st udied st ring players on a tenolol vs. pla cebo
a nd found th e ac t ive dru g to d ecr ease various stage fri ght symptoms (on a sta ge fri ght rating scale cons ist ing of two cog nitive qu estion s, two ph ysical questions and
two technical/ m usical qu estion s) d uring t he pe rform ance bu t not im m ed ia t ely before
it. As in o t he r st udies, t he act ive drug block ed t he during-pe rfor m a nce ta chycardia.
Uri nary ca techo lamine m easurem ents were co ns iste n t with sympathoadrenal act ivation by st ress; th e a te no lol was felt to ac t by peripheral bloc kade of suc h activation
a nd was associa te d with som e improvem ent in technical pe rfor m a nce. Th e main
sym pa t he tic ac tiva t ion occ ur re d 90 sec o nds before th e begi nning of t he perform ance.
A sho rtcom ing of t his st udy was th e rel a tive lack of scree ning fo r phys ical symptoms.
Gates, Saege rt , W ilson et a I. (5) st udie d singe rs with 20 mg, 40 mg, a nd 80 mg of
nad olol a nd showed a limitati on of in traperform an ce hea r t rat e with all doses. The
m usic j udges' ra tings for t he perform a nces sho wed a slight preference for performance with 20 m g nad olol vs. placeb o, while the high e r doses resul t ed in perform an ce
judged as sig nifica n t ly poorer. This corre la te d to th e com me nts by some subjects th at
t he high er doses decr eased th eir ene rgy . Th e a u t hors d id not report th e effec t of th e
me d ica tion on specific sym ptoms .
Liden a nd G ott fri es (6) st ud ied instru m en tal musicians on e it he r 50 mg or 100
mg a lpre no lol vs. placeb o a nd fou nd a clear improve m ent in severity of se lf-re po rts in
two sym p tom grou ps; palpit ation , incr eased m uscle to ne , a nd t remor were g ro upe d
as th e "ca techo la m ine synd ro me" while o t he r less specific symptoms (e.g., un easiness, irrit ability, a nd head ache) were g ro upe d as "ot her sym ptoms." No differen ce
was found bet ween th e two do ses of a lpre no loI. No assessme n t of th e qu ality of
m usical perfor mance o r obse rve r ratings of signs of anxie ty were reported.
J am es, Burgoyn e an d Savage (3 1) used pind olol on ins trumental musicians in a
placeb o-controll ed st udy. The subjects' pu lse and blood pr essure were measured
before th e performance . The subjects rat ed both t he ir level of a nxie ty and th ei r own
pe rform an ce, a nd th e perform ance was eva luate d by a n expe rie nced professional
musician. Th e pindolol g ro up showed signifi cantly lower pul se an d systolic blood
pressure with th e ac tive dru g, a nd a lowe r a nx iety se lf-rat ing and higher performance
ratings by t he ra te r in th e grou p of " bette r" pla ye rs. This study did not sp ecificall y
ad dress th e various phys ica l sym ptoms of pe rfor m a nce anxiety.
Br ewer (32) st udied th e effect of ox prenolol vs. placebo on a "high anxi et y"
grou p of universit y st ude n ts tak ing exa mi nations . H e started subj ects at 10 mg
prop ranolol a nd incr eased doses until the subject's res ting pulse was slowed to 60 :± 5
BPM. H e co nclude d that th ere was a n improved perform an ce on exam inations by
th ose wh o wo uld o the rwise be adverse ly a ffec te d by high levels of anxi ety, espec ia lly
t hose st uden ts with promi nent ca rdio vascula r sympto ms .
T a ggart, Carru t he rs a nd Some rville ( 13) stud ied t he effec ts of 40 mg oxpren olol
on su bjects speaking before an a ud ie nce . EKG mo nitori ng of a gro up of his subj ect s
with coronary a r tery disease revealed ST d epression whe n t hose subjects spoke. T he
ox pre nolol improved th es e EKG abno r malities a nd block ed t he anxiety-associat ed
tach ycardia ; th eir st udy did not add ress th e ot her phys ica l sym ptoms or mental
symptoms of perform an ce a nxie ty.
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Drew, Barnes a nd Evans (33) stu di ed t he effec ts of 120 m g propra nolol vs.
placebo on st ude n t volun teers performing tests of verbal reas oning a nd m en tal
a rit h me tic. The act ive drug group was shown to have im proved sco res in bot h
perform an ce t ask s. U ndesirable effec ts were seen in nearly ha lf of th e subjects
receiving propranolol; th e mo st fre q ue n t ly re port ed sym ptoms were nausea , head ac he, a nd weak legs. The m aj or benefit of t reat m ent was seen in a subgro up who
described th emselves as having a nxie ty sym pto ms . As on ly a sin gle do se was used in
this st udy , it is not possibl e to d e termine whet her som e of th e cite d side effects were
dose rel at ed.
Siitone n a nd Jan ne (34) st ud ied th e effec ts of 40 mg oxpre no lol on bowl ers in a
placebo-controlled d esign. The oxpre no lol pr event ed pe rform an ce-r ela ted tach ycardi a a nd was associa te d with im proved bowling scores in a subgroup of subj ect s who
had ex hi bite d a sig nifica n t ly high e r heart ra te before, d uring, a nd aft er th e co m pe t ition. This findin g is co nsis te n t wit h th e hypoth esis th at persons with subs tant ia l
perform an ce a nxie ty sym p to ms m ay have a high er d egree of cardiovas cu lar reactivity
to performance st res sors than other peopl e.
G orm an, Lieb owitz a nd Fyer e t a l. ( 12) st udied te n subj ects who met t he
DSM-III criteria for soc ia l ph ob ia. The subjects all suffe red from variou s ph ysical
com pla in ts in soc ia l se tt ings; of th ese sym p to ms , pal pit a tion s, sweating, and tremor
were th e most com m only report ed. No effor t was mad e to separa te a performan ce
a nxie ty subtyp e from gen eralized social phobia in this st udy, t ho ug h non e of th e te n
had a hist o ry of spo n taneous panic a ttacks. Five of t he subjects had a hist ory of
d epression , a nd five had a history of a lcoh ol a buse. Doses ranged from 50 mg to 100
m g a te no lol daily for th e six week s of th e trial. Ni ne of th e ten pati ent s in th is ope n,
un controll ed st udy cite d " mode ra t e" or " mar ked" improvem en t in th eir socia l
phobia symptoms. Sp ecific sym ptom improvem ent and ph ysiological measures were
not addressed .
Lieb owit z, G orm an a nd Fye r e t a l. ( 11,14) st udi ed 87 patients wh o m et th e
DSM-III cr ite ria for socia l ph obi a in a ra ndom ized placebo-controlled trial of a te no lol
a nd th e monoamine oxidase inhibitor ph enel zin e. Dail y a te no lol dos es were eit he r 50
or 100 mg (m ean, 95 mg) whil e dai ly ph enelzine do ses ra nged fro m 45-90 mg (m ean ,
72 m g). Assessm ent s included seve ral a nxie ty and depression inventories , plu s a
soc ia l ph obi a scale, which included 12 di scr et e perfor m ance fears . Th ei r findin gs were
that ph en el zin e was more effect ive for ge ne ralized soc ia l ph obia , wh ile at enolol was
helpful for th e dis cr et e performance-rel at ed social ph obi a . A di fficulty with this st udy
is th e lack of cle ar distinctions between th e ge ne ra lized versus performan ce-relat ed
socia l phobia gro ups.
PHARMACOLOGICAL PROPERTIES OF T HE BETA-ADRE ERGIC BLOCKING
AGENTS STUDIED

The ph armacolo gic properti es of th e beta-adren ergic blockin g ag e nts used in th e
pr eviously di scus sed performance a nxie ty a nd soc ia l ph obi a st udies are summ arized
in T abl e 3. The cho ice of a specific bet a- adren ergic blocking agent fo r the treatm ent
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of t he phys ica l symptoms of perform an ce anxi ety depends substant ially o n two
ph ar macological pr ope r ti es: lipid vs. H 20 so lubi lity and receptor se lect ivity. At en olol
is a ca rdioselect ive (i.e ., beta-on e sel ective) , hydrophilic age n t (20,27,35,36). As a
result, it s bet a-adren ergic actions a re more specific to th e heart a nd to blocking
t ach ycardia. Becau se of it s hydrophilicit y, a t e no lol has rel a tively poor blood-brain
barrier pen etration a nd thus less risk of th e CNS sid e effec ts occa sionally rep or t ed
with more lipophil ic beta-adren ergic block ers suc h as pr op ran olol. T he finding in t he
studies cite d ( 12,30) that at eno lol ha s so me succes s in blo cking th e sym pt om s of
pe rfo rmance anxi ety supports t he hypo t hesis that su ch sym p to ms a re medi a ted by a
periphe ra l mechanism .
Propra nolol, by con tras t, is a nonsel ective a nd lip ophilic age n t. T he inciden ce of
CNS sid e effec ts from bet a-adrenergic blockad e is report ed to be g rea te r with t he
more lipoph ilic age nts , ye t is still infrequ ent , es pec ia lly a t clinica lly-a cce pt abl e doses
(35). Based on th e th erap eu t ic effec t of bet a-adren ergic blo cking ag ents on esse nt ia l
tremor, it has been recomm ended that a nonselective a gent be used wh en tre mor is a
significant target symptom (27,36) .
Of th e other beta-adren ergic blocking age n ts cite d in th e above st udi es, only
pindolol (moderat ely lipophilic and non selective ) and nad olol (hyd rop hi lic a nd
non sel ective) a re in co m m on use in th e U.S. As a ll of th e m ention ed bet a- ad re ne rgic
blocking age n ts cite d showed at least so m e effec t in sympt o matic co nt ro l of performance anxiet y, and no psychiatric sid e effec ts were report ed in th e stu d ies , it wou ld

TABLE 3.
Pharmacological Properties of Beta-Adrenergic Blocking Ag e n ts Used in Performance
Anxiety and Social Phobia Studie s: (32, 33 ,3 7-40)
Bet a-Block er: Lipophi licity:

Relative
Cardiose lectivity: Pot en cy:

Effecti ve ness:

high

(- )

1.0

m od erat e

(- )

0.5-1.0

Alprenolol
( 1 study)
Pind olol
(I study)
Nad olol
(2 st ud ies)

moderat e

(- )

0.3-1 .0

moderate

(- )

6.0

Effective in 1 study (3 1)

low

(- )

1.0

At enolol
(3 studi es)

low

(+ )

1.0

Effecti ve in I stu dy (3)
Effecti ve at 20 m g dos e, ineffecti ve a t 40 m g, 80 m g dose
in I st ud y (5)
Effect ive in 2 s t ud ies (12, 30)
Effective in " D iscre te Socia l
Phobia " Subgroup in 1 study
( 11, 14)

Propra nolol
(4 studies)
Oxpren o lol
(3 st udi es)

Effective in 4 st udi es ( I, 4, 32,
34
Effecti ve in 2 st ud ies (2, 13)
Effect ive in " H igh Ca rdiovascula r React ivity" subg rou p
in I study (33)
Effective in I st udy (6)
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see m a ppro pr iate to use a ny of t hem clinica lly. If t re mo r shou ld not be co nt ro lled
with a te no lol, a change to a non sel ecti ve agent may be tried. Shou ld th e pati ent have
a history of CNS side effec ts from a lip ophilic beta-adren ergic bloc ker, a switch to a
less lipophilic ag ent cou ld be co ns ide re d .
OTHER PHARMACOLOGIC AND NON PHARMACO LOG IC T REATMENTS OF
PERFORMANCE ANXIETY

When perform an ce a nxie ty is pr esent with t he ge ne ralize d type of social phobia,
ph armacologic treatm ent with th e monoamine oxidase inhibi tor phene lzin e ca n be
cons ide re d (14,20 ,21 ,37). Do ses to co nside r range between 45 an d 90 mg daily. The
usual ca u t ions a pply regarding co m plia nce with a tyr amine-free d iet and awaren ess
of possibl e tyr amin e reaction.
For sympt oms of perform an ce a nx ie ty, ph arm acologic trea tment should includ e
benzodiaz epin es onl y with great ca u tion. The risk of a lcohol ab use in t hese pati ents
m ak es th e chance of benzodiazepine a buse sig nifica n t. If used for thi s purpose ,
benzodi a zepines sho uld be shor t half-life age n ts (e .g ., alprazo lam, lo ra ze pa m) a nd
used prim arily on a limit ed , PRN ba sis.
Because of th e possible confus ion regarding panic di so rd e r vs. social phobia , it
may be that som e pat ients presenting with perform an ce-r el at ed a nxiety symptoms
a re in fa ct suffe re rs of primary panic disord er. If this is a clinica l possibility, the
pati ent may respond bett er to tricyclic a n t ide pressa n ts (22).
For nonpharmacolo gic managem ent of perform an ce a nx ie ty sym ptoms, va rious
int ervent ions have been recomm end ed . Anxi et y m an a gem ent training involves exposure to th e phobic sit uat ions or a sim ila r sit ua t io n. An apt exam ple is Toastmaster's
C lub for th ose with public speaking ph obi a ( 15,37). Rela xat ion training can be
co m bine d with th e expos ure to th e phobic sit uat ion . The ex posure th e ra py may be
most su ccessful wh en com bine d with cog nitive th erap y, wh erein th e th era pist helps
th e patient to correct incorrect cog nit ions abo u t th e perceived co nsequences of his
ph ysical sym pto ms, a nd to repl ace negative expec ta t ions wit h more hopeful ones
regarding performance (37) .
Social skills tra ining can be cons ide re d for those patient s wit h associa ted socia l
dysfunction. This may require a g ro up form at a nd m ay incl ude assis tance in
co m m u nica t ion a nd ass ertiveness. This m ay be particul arly va lua ble for the pati ent
who m eet s th e crite ria for avoidant personality di sorder ( 15).
Wha tev er approach is taken for pati ents with th e perform an ce a nx iety subtype
of socia l ph obi a , pharmacologic treatm ent co m bine d wi th psych ologic in te rve n tion
sho uld hav e as a co m mo n goal sym pto m reducti on , increased confi dence in good
perform an ce, and cons olida te d, lon g-lasting improvem ent (7).
SUMMARY AND RECO MMENDAT IO NS

The evalu ation and managem ent of perform an ce a nx iety m ay challenge th e
psych iatris t's diagnost ic, pharmacologic, m edi cal , a nd psych oth erapeu tic skills. The
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patient who present s for help wit h disabling perform a nce anx iety sym pto ms, particularly t he mu sician, speake r, ac to r, or at hlete, m ay be fac ing a ca ree r-t hre a te ning
pr obl em. The re is little marg in for erro r in perfor m ance for those who pursu e th ose
ac tivities professionall y.
Careful history taking for th e ph ysical sym pto ms of perform a nce-rela ted sympath etic nervou s syste m discharge (t ach yca rdi a /palpitation s, sweat ing, and tremor
bein g th e most co m monly m ention ed ), co nside ratio n of a diagnosis of panic disord er
if suc h sym ptoms firs t a ppeared spon taneous ly and a re not a lways relat ed to
performance, a nd di fferentiation of lim ited social phobia from th e more global
di sorders ge neralized soc ia l ph obi a an d avo ida n t personality disord er are esse ntial.
The psychi atrist mus t a lso rema in vigi la n t for concurrent depression , subs ta nce
a buse / depe nde nce, and ot he r ph obi as t hat m ay be presen t in this population.
O nce havin g d etermined th at a pat ient does ind eed suffer from a limit ed soc ial
ph obi a /performance a nx ie ty, th e clinicia n may cons ide r beta-adren ergic block er
th erapy. One mu st be mindful of resting br ad ycardi a , di a betes m ellitus, rea ct ive
airway di sease, Rayn aud's ph en om en on a nd ot he r m edi cal conditions which wou ld
m ak e bet a-bl ock er th erap y problem atic. When bet a-block e r th e ra py is to be tried , th e
clinicia n ca n sta r t at a low dose (e.g., proprano lol 20 mg to 40 mg or at enolol 50 mg)
a nd tit rate up wa rd s to co nt ro l troubl esom e sym ptoms (38). Th e patient should be
taugh t to check his pul se a nd no t tak e high er doses if t he resting pu lse is less th an 60
BPM. Pulse a nd blood pressu re sho uld be checked on office visits. If th e pati ent has a
history of CNS side effects from bet a-adren e rgic blockade (including th e ophthalmic
pr ep a rat ion s of timolol, levobunolol, a nd be taxolol), th ese agents shou ld be used ve ry
ca u tious ly.
For patient s who face a sym p to mat ica lly ph obi c stim ulus on ly on occasion (e.g.,
th e mu sician who has a n occasional difficult a ud ition or per form an ce), th e use of
bet a-adren e rgic blockad e on a PRN basis one or two hours pri or to performance may
be ade q ua te . For th e limit ed social ph obi c who mu st face his ph obi c challenge and
perform well dail y, dail y dosin g of th e me dica tion may be necessary. For th e athlet e
who need s fine motor co n trol (e .g., the a rc he r, go lfer, or billiards pla yer ), t he
cli nician mu st learn wh ethe r th e use of beta-blocke rs wo uld violate th e rules of t he
sport's gove rn ing body. Bet a-adren ergic block ing agents are not among subst an ces
banned for Ol ympic a t hle te s (39).
It may be mo st effec tive to com bine ph armacothera py with behavioral th erap y,
cog n itive res t r uc t u ring a nd wh en need ed soc ial skills t ra in ing to ach ieve lasti ng
result s for this challe ng ing clinical pr obl em.
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